Corcept Therapeutics, Inc. (CORT)

[PennyStockpick]

short $CORT, they released horrible financials on Friday http://finance.yahoo.com/q/is?s=cort

[Thurly]

Look at their revenue and break even forecasts.

[yogispappa]

Hi Thurly, I think company misspoke about TNBC results 1 st half 2015, I remember hearing that also. Last CC CEO said the company would have the results, and would be made public 2nd half 2015. Hopefully sales continue to increase. Good Luck

[Thurly]

I expect CORT's shareprice to rise an average of .50 per quarter for the next 5-6 quarters. If they have good results in triple negative breast cancer in 1H15, they will go higher. If they don't have good results, I expect a hit but they will recover to the trend line of .50/quarter after the turmoil subsides.

FWIW

Best. Hope all is well.

Leslie

[PGG76109]

Thurly you have any current thoughts on CORT?
Hope your doing well buddy take care. PG

[Big_Money_Upward]

getting close to the 5-yr high, that's a catalysts

[Thurly]

We're range-bound until the next catalyst, which is likely the May 7th earnings call. Will uptake of Korlym for Cushing's decelerate? That's what Belanoff hinted at last call. I'll wait and see but, I wonder . . .

Then the interim data . . .

[Big_Money_Upward]

just bought some CORT at $4.11

[Big_Money_Upward]

sneaky guys ran this up in the last hour. woundn't have seen it if i didnt set like 5 alerts on it.

[Thurly]

Is Belanoff saying that in 2014 they will net revenue of $56.2M?

The press release said:

“Korlym® revenue increased 56 percent in the fourth quarter compared to the prior quarter,” said
K. Belanoff, MD, Corcept’s Chief Executive Officer. “We expect our momentum to continue in 2014,
with Korlym revenue reaching the $24 million to $28 million range for the year.”

If "our momentum" (56%) is to continue, 24-28M has to represent Q414 net revenue.

56% growth starting at $4.1M Q413 net revenue would equate to quarterly revenue in 2014 of:

6,396,000.00 Q1
9,977,760.00 Q2
15,565,305.60 Q3
24,281,876.74 Q4

A 457% growth rate.

Yes? Or maybe he's not being specific about the rate of growth, just that positive momentum will continue through 2014.

[Thurly]

Sept. 1, 2013
http://www.sciencedirect.com/science/article/pii/S0006322312010876
Mifepristone Alters Amyloid Precursor Protein Processing to Preclude Amyloid Beta and Also Reduces Tau Pathology

Results
Mifepristone treatment rescues the pathologically induced cognitive impairments and markedly reduces amyloid beta (Aß)-load and levels, as well as tau pathologies. Analysis of amyloid precursor protein (APP) processing revealed concomitant decreases in both APP C-terminal fragments C99 and C83 and the appearance of a larger 17-kDa C-terminal fragment. Hence, mifepristone induces a novel C-terminal cleavage of APP that prevents it being cleaved by a- or ß-secretase, thereby precluding Aß generation in the central nervous system; this cleavage and the production of the 17-kDa APP fragment was generated by a calcium-dependent cysteine protease. In addition, mifepristone treatment also reduced the phosphorylation and accumulation of tau, concomitant with reductions in p25. Notably, deficits in cyclic-AMP response element-binding protein signaling were restored with the treatment.

[Thurly]

Patent Application/Publication, Jan 2, 2014
Use of Mifepristone for the Treatment of Amyotrophic Lateral Sclerosis
http://www.google.com/patents/US20140005158

CLAIMS(20)
What is claimed is:
1. A method for ameliorating the symptoms and/or slowing the rate of disease progression in a patient diagnosed with amyotrophic lateral sclerosis (ALS), the method comprising administering a therapeutically effective amount of a glucocorticoid receptor specific antagonist (GRA) to a subject in need thereof, with the proviso that the subject not be otherwise in need of treatment with a glucocorticoid receptor antagonist.

[Investor100]

CORT @ Stockcharts

A beastly run in 2014!

Pipeline Progress at Corcept
http://finance.yahoo.com/news/pipeline-progress-corcept-210502627.html
We remind investors that Corcept enjoys orphan drug designation for Korlym from the U.S. Food and Drug Administration (:FDA) for the approved indication.

[Investor100]

Cort@ Stockcharts

http://openinsider.com/search?q=cort

http://finance.yahoo.com/news/corcept-therapeutics-announces-oncology-development-133000844.html

[Investor100]

CORT @ Stockcharts

Nice upward movement!

http://finance.yahoo.com/news/corcept-therapeutics-announces-third-quarter-213817746.html

[HIM]

CORT nice move today.. It is back on my watch.

[PGG76109]

Wow nice morning pop on no news and not one post here?
Oh well just keep going up CORT! PG

[PGG76109]

Thanks guys. Will look into that. Tired of nothing happening at my major hold so been building a position here before I die of boredom. PG

[Thurly]

New BSR Alert on Corcept, if you subscribe. Cannot share details due to licensing agreement.

[north40000]

Charter member monthly subscription is $25. BSR has only monthly subs. now. Monthly rate for new subscribers is different, perhaps 2x.

BSR's coverage of CORT is excellent. SGEN too.
Good to see you folks here. One of these days BSRDavid will return to PPHM for a 2nd lookover--
I may have to needle him on that.

Further info here, I think:

www.BiotechStockResearch.com/latestIssues.php

[Thurly]

I'm here, but the best source of info is still BSR. Also, a scholar google search of Belanoff yields quite a few relevant articles on compounds that Corcept controls. BTW, BSR has just initiated monthly billing for subscriptions so you don't have to plop down $600 a year in one chunk. And I think the subscription doesn't have to be for a full year, but I'm not sure on that.

[north40000]

I have had a position since 2009, added more in 11/2012, + 22%-38% so far. David Miller of BSR covers it. co3aii and I followed some AMLN money here early.

[PGG76109]

Wow this board is dead as a door nail.
I am slowly building a position anyone else out there?
PG

[PGG76109]

Hey North40k nice to see a name I know. I have started building a CORT position today with a small starting purchase of 500 shares. I will add over time and as I understand more. All the best PG

[MissionIR]

CORT Video Chart 4/19/2013

http://www.missionir.com/videos.html

[mannyx99]

Heres $CORT Buy Alert - https://twitter.com/livingstonceo/status/322915709397127168/photo/1

[nogoodtrader]

Lots of buying today looking good.

[Penny Roger$]

Nice charts!

[Penny Roger$]

~ $CORT ~ Parabolic SAR Buy Signals ~ Criteria alert for last trading session!

$CORT has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "CORT" utilize the links that follow.
Search FaStlane's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2011&SearchStr=ParSarBuyScan ~
Search FaStlane's posts for symbol "CORT": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2011&SearchStr=CORT ~
Search Ihub for "CORT" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CORT ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~

[blue finch]

Good entry point @1.80.

[gertje54]

quarterly report out: disappointing revenue , only 40% increase.

[blue finch]

Should be changing. Starting soon. I'm almost done with a reality check. Lost opportunity. With stocks like this one btw

[banchrima]

Me too ... meanwhile we are used re. the mixture of being disappointed, angry, hopeful and confident ... changing, LOL.

[blue finch]

Sorry only 1 month I would like to forget about lbsr for 3 months actually

[banchrima]

Re. doghouse ... cooperation of mod and admin ... first one has fool´s license (OT, bash, badmouth etc.) but I get banned ... as you say something wrong (not at board but with IHUB) ...
GLTY

[surf1944]

CORT trending higher, looking for $2.59 as next break.....

[blue finch]

Any. Guess as to. What. The. CT. order on December 12 was all about?

[gertje54]

Well, I guess that management has seen a significant increase in demand for their product(s) to purchase shares so obviously. Estimates for Korlym are promising. 10 Q will reveal more.

[blue finch]

Well someone is pushing the share price higher And we are the beneficiaries

[Bio-Wire]

Corcept is going to need some pretty good sales figures this year to exceed the market's expectations. Can't have more of the same

http://www.bio-wire.com/archives/505

[surf1944]

http://www.secform4.com/insider-trading/1088856.htm

[blue finch]

4 dollars would be a very nice price

[manny t]

CORT,

Piper Jaffray initiates coverage on Corcept Therapeutics ( NASDAQ : CORT ) with an Overweight rating.

Price target of 4 dollars.

Stock was up 10.13% today to 1.63,after this rating yesterday

Janney starts Corcept with Buy rating and fair value of 3 dollars.

Manny

[antlex10]

All aboard CORT is leaving the station!! CORT is ready to fly IMHO!

[TaxiCaT]

Another 10% day - link back, got in this at $1.35 and now trading at $1.65 - up over 20k here and counting - I see $2.00 before I will sell -

[TaxiCaT]

Still holding - still looking for $2.00

[north40000]

Doubled my holdings on 11/12 @ $1.34.

[Tommy]

$CORT - Insider Buying Highlights Reasons I Took A Flyer On This $1.40 Pharma Stock

http://seekingalpha.com/article/1043641-insider-buying-highlights-reasons-i-took-a-flyer-on-this-1-40-pharma-stock

... "7 reasons CORT is solid speculative play is $1.40 a share:

Two separate directors have bought approximately $800K worth of new shares in November. Most purchases were made at higher than the current stock price.
The company has over $70mm in net cash on its balance sheet. This would fund over 2 ½ years of operations at the company's current burn rate.
The median price target on CORT held by the 6 analysts that cover the stock is $3.65. There is a wide range to these targets (Low Target: $1.10, High Target: $8). Throwing out the high and low target prices gives us a median price target of $3.20 on the shares, more than double the current stock price.
Analysts have a consensus revenue target of over $24mm for FY2013 currently on CORT. This is quadruple the under $6mm in revenue the company is tracking to book in FY2012.
In February the FDA approve Korlym (mifepristone) 300 mg Tablets as a once-daily oral medication for a very specific conditions found in some Cushing's Syndrome patients. Corcept is also currently conducting a Phase 3 study of the effects of Korlym on the psychotic features of psychotic depression. The FDA has granted Corcept "Fast Track" status for this compound. The company is in the early stages of testing to see if this drug can counteract the weight gain impacts of certain antipsychotic drugs as well.
Given CORT's small market capitalization (around $75mm after net cash subtracted), growing sales and possible new uses of its signature product; I could see it as a logical acquisition target by a bigger player with a larger distribution network and sales force.
The stock has traded in a range of roughly $1 to $5 a share. It is much closer to the bottom of that range than the top (See Chart)." ...

[TaxiCaT]

Hitting $1.53 as we I type -

[TaxiCaT]

Took a decent size position today at $1.35 - really like the chart for a bounce to $2.00 -